Cytochrome p450 comprises a superfamily of heme-thiolate proteins named for the spectral absorbance peak of their carbon-monoxide-bound species at 450 nm. The p450 superfamily, which has members in every class of organisms, including Archaea, is thought to have descended from an ancestor gene that existed more than 3 billion years ago.One of the biggest multigene families has subsequently been created as a result of repeated gene duplications. These enzymes stand out for the variety of reactions they catalyze as well as the variety of chemically diverse substrates they act on. The oxidative, peroxidative, and reductive metabolism of endogenous and exogenous substrates like environmental toxins, agrochemicals, plant allelochemicals, steroids, prostaglandins, and fatty acids is supported by cytochrome p450s. Drug interactions and interindividual variability in drug metabolism are two of the most important issues in clinical pharmacology, and cytochrome p450s in humans are best known for their central role in phase I drug metabolism.
| Structure | Cat No. | Product Name | CAS No. | Product Description |
|---|---|---|---|---|
|
V73970 | CYP1B1-IN-2 | 727730-24-7 | CYP1B1-IN-2 (compound 9j) is a potent and specific inhibitor of CYP1B1 (cytochrome P450 1B1) with IC50 of 0.52 nM. |
|
V73969 | CYP1B1-IN-3 | 2872575-51-2 | CYP1B1-IN-3 is a potent and specific inhibitor of CYP1B1, with IC50s of 6.6, 347.3, and >10000 nM for CYP1B1, CYP1A1, and CYP1A2 respectively. |
|
V73964 | CYP1B1-IN-5 | 176442-56-1 | CYP1B1-IN-5 (Compound 6q) is a potent and specific inhibitor of cytochrome P450 1B1 (CYP1B1) with IC50 of 4.7 nM. |
|
V80224 | CYP2A6-IN-1 | CD-6 is a flavonoid CYP2A6 inhibitor (IC50= 1.566 μM). | |
|
V78967 | CYP450-IN-1 | CYP450-IN-1 (compound 2e) is a potent inhibitor of CYP450. | |
|
V73983 | CYP4A11/CYP4F2-IN-1 | 502654-40-2 | CYP4A11/CYP4F2-IN-1 is a potent dual (bifunctional) inhibitor of cytochrome P450 (CYP) 4A11 and CYP4F2 with IC50s of 19 nM and 17 nM, respectively. |
|
V73937 | CYP4A11/CYP4F2-IN-2 | 2280834-99-1 | CYP4A11/CYP4F2-IN-2 (compound 15) is an orally bioavailable inhibitor of CYP4A11/4F2 with IC50s of 120 nM and 220 nM, respectively. |
|
V73955 | Cytochrome P450 reductase | 9039-06-9 | Cytochrome P450 reductase is a NADPH-cytochrome reductase. |
|
V73958 | DDMS (Dibromo-dodecenyl-methylsulfimide) | 206052-03-1 | DDMS (Dibromo-dodecenyl-methylsulfimide) is a selective inhibitor of 20-HETE production. |
|
V73950 | Desmethylcitalopram hydrochloride (DCIT hydrochloride) | 97743-99-2 | Desmethylcitalopram (DCIT) is the bioactive metabolite of citalopram. |
|
V67326 | Dibenzylfluorescein (DBF) | 97744-44-0 | Dibenzylfluorescein (DBF) is a fluorescent probe (Fluoresecent dye) and a specific substrate for cytochrome P450 (CYP) isoforms such as CYP3A4, CYP2C8, CYP2C9, CYP2C19 and aromatase (CYP19). |
|
V73949 | Diosmetin-d3 (Diosmetin-d3) | 1189728-54-8 | Diosmetin-d3 is the deuterated form of Diosmetin. |
|
V73968 | DL-Acetylshikonin | 54984-93-9 | DL-Acetylshikonin is a non-selective, reversible inhibitor of cytochrome P450 with IC50 of 1.4-4.0 μM. |
|
V32172 | DMU2139 | 1821143-80-9 | DMU2139 is a potent and specific CYP1B1 inhibitor, with IC50s of 9 nM and 795 nM for CYP1B1 and CYP1A1, respectively. |
|
V20588 | ent-Atorvastatin | 501121-34-2 | ent-Atorvastatin [(3S,5S)-Atorvastatin] is an inactive isomer/enantiomer of Atorvastatin, which is a HMGCR (HMG-CoA reductase) inhibitor and an approved blockbuster drug of the statin class of LDL cholesterol-lowering/hypolipidemic drug. |
|
V73984 | Eriodictyol chalcone | 14917-41-0 | Eriodictyol chalcone has anti-aromatase and anti-17β-HSD activity. |
|
V20900 | Fadrozole HCl (CGS-16949A) | 102676-31-3 | Fadrozole(CGS 16949A)is a highlypotent and selectivenonsteroidal aromatase inhibitor (IC50 of 6.4 nM) with potential antineoplastic activity. |
|
V69477 | FGFR-IN-10 | 2847092-41-3 | FGFR-IN-10 is an orally bioactive FGFR and Cytochrome P450 (CYP) inhibitor. |
|
V79416 | Fipronil-13C6 (Fipronil-13C6) | Fipronil-13C6 is 13C (carbon 13) labelled Fipronil. | |
|
V69497 | FLT3-IN-17 | 2758999-62-9 | FLT3-IN-17 inhibits the activity of CYPs and FLT3 mutants (IC50s: <0.5 nM for D835Y). |
Products are for research use only; We do not sell to patients
Copyright 2020 InvivoChem LLC | All Rights Reserved
